GlassScriptPhysician profile
Sachit Sharma
NPI 1346691839
$2,032.72
in general payments reported to CMS, 2019-2025
20 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $268 · 2023: $273 · 2024: $351 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,601 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,600.95 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $707.00 | 2022-2025 | Tremfya, Stelara |
| Abbvie INC. | $608.86 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $136.95 | 2022-2023 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $72.27 | 2024-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.31 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $52.57 | 2025 | Vegzelma |
| Genzyme Corporation | $46.06 | 2024 | |
| Madrigal Pharmaceuticals | $40.39 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $39.54 | 2025 | Voquezna |
| Pfizer INC. | $38.83 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $37.82 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $32.90 | 2025 | Sucraid |
| Ardelyx, INC. | $28.43 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $25.76 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $24.20 | 2025 | Suflave, Sutab |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.25 | 2025 | Omvoh |
| Sandoz INC. | $18.82 | 2024 | Hyrimoz |
| Boston Scientific Corporation | $17.50 | 2024 | Compliance Endokit |
| Conmed Corporation | $15.15 | 2024 | Conmed Dilation, Conmed Biliary, Conmed Generators |
| Merit Medical Systems INC | $11.11 | 2024 | Endomaxx Stent and Delivery System, Alimaxx-Esophageal Stent/Delivery System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sachit Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.